Literature DB >> 12487775

Thoughts on prevention of thyroid disease in the United States.

David S Cooper1, E Chester Ridgway.   

Abstract

In the realm of preventive medicine, there are three distinct types of prevention that can be defined. Primary prevention is the prevention of new disease in previously healthy individuals, usually achieved by decreasing risk factors for disease. Secondary prevention is the prevention of progression of mild or latent disease to more severe disease, and typically involves screening for occult disease. Tertiary prevention is the term used by some to describe medical care intended to improve already established disease. The role of primary prevention of thyroid disease in the United States is uncertain, because iodine deficiency is not clearly known to be a problem. In the case of secondary prevention of thyroid disease, this would necessarily involve screening of individuals for subclinical hyperthyroidism or hypothyroidism with thyrotropin (TSH) testing. Using data from a large prevalence study and from the 2000 U.S. Census, it can be calculated that approximately 15 million adults have unrecognized thyroid disease, mostly subclinical hypothyroidism. If detected, secondary prevention might also entail treatment with antithyroid drugs/radioiodine or thyroxine to prevent sequelae or progression to a more advanced degree of thyrotoxicosis or thyroid failure, respectively. Over the next 20 years, it can be calculated that approximately 5 million people, mostly with subclinical hypothyroidism, will progress to overt disease. Tertiary prevention of thyroid disease would involve avoiding iatrogenic disease, such as thyroid hormone overdose. From epidemiologic data it can be calculated that approximately 600,00 elderly individuals have iatrogenic hyperthyroidism from thyroid hormone overdose, putting them at risk for atrial fibrillation and osteoporosis. Together, these data suggest that the notion of preventive medicine in the United States should be expanded to include thyroid disease as a target for secondary and tertiary intervention.

Entities:  

Mesh:

Year:  2002        PMID: 12487775     DOI: 10.1089/105072502761016566

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

1.  Vasculitis and anti-thyroid medication.

Authors:  Sofia Lionaki; Susan L Hogan; Ronald J Falk; Melanie S Joy; Caroline E Jennette; Patrick H Nachman; J Charles Jennette
Journal:  Nephrol Dial Transplant       Date:  2007-12-21       Impact factor: 5.992

Review 2.  Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment.

Authors:  Peter Laurberg; Stig Andersen; Inge Bülow Pedersen; Allan Carlé
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  The TSH upper reference limit: where are we at?

Authors:  Peter Laurberg; Stig Andersen; Allan Carlé; Jesper Karmisholt; Nils Knudsen; Inge Bülow Pedersen
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

4.  Development and preliminary validation of a machine learning system for thyroid dysfunction diagnosis based on routine laboratory tests.

Authors:  Min Hu; Chikashi Asami; Hiroshi Iwakura; Yasuyo Nakajima; Ryousuke Sema; Tsuyoshi Kikuchi; Tsuyoshi Miyata; Koji Sakamaki; Takumi Kudo; Masanobu Yamada; Takashi Akamizu; Yasubumi Sakakibara
Journal:  Commun Med (Lond)       Date:  2022-01-19

Review 5.  Hypothyroidism as a risk factor for cardiovascular disease.

Authors:  Bernadette Biondi; Irwin Klein
Journal:  Endocrine       Date:  2004-06       Impact factor: 3.633

6.  Epidemiology of hyperthyroidism in Iran: a systematic review and meta-analysis.

Authors:  Sayed Mahmoud Sajjadi-Jazi; Farshad Sharifi; Mehdi Varmaghani; Hamidreza Aghaei Meybodi; Farshad Farzadfar; Bagher Larijani
Journal:  J Diabetes Metab Disord       Date:  2018-11-16

7.  Towards a further understanding of prenatal thyroid theory of homosexuality: Autoimmune thyroiditis, polycystic ovary syndrome, autism and low birth weight.

Authors:  Osman Sabuncuoglu
Journal:  Ment Illn       Date:  2017-10-23

Review 8.  Primordial and Primary Preventions of Thyroid Disease.

Authors:  Fereidoun Azizi; Ladan Mehran; Farhad Hosseinpanah; Hossein Delshad; Atieh Amouzegar
Journal:  Int J Endocrinol Metab       Date:  2017-10-07

9.  Evaluation of circulating cell free DNA in plasma as a biomarker of different thyroid diseases.

Authors:  Ozge Caglar; Begum Cilgin; Mustafa Eroglu; Akin Cayir
Journal:  Braz J Otorhinolaryngol       Date:  2019-02-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.